Overview
Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies
Status:
Recruiting
Recruiting
Trial end date:
2021-05-01
2021-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of allergic conjunctivitis using an antigen challenge modelPhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Vanda Pharmaceuticals
Criteria
Inclusion Criteria:- At least 18 years of age of either gender and any race
- Able to provide written informed consent and sign the HIPAA form
- Willing and able to follow all instructions and attend all study visits
Exclusion Criteria:
- Able and willing to avoid all disallowed medications during washout and study period